Hikma to market BioCryst drug in MENA region

11th Jan 2010 14:32

Hikma Pharmaceuticals has signed an exclusive agreement to market BioCryst's H1N1 treatment peramivir with governments in the Middle East and North Africa (MENA) region. 'This agreement reinforces our position as the partner of choice in the MENA region,' said chief executive Said Darwazah.'BioCryst has received peramivir emergency use enquiries from a number of countries in MENA, and we look forward to working with BioCryst to make peramivir available during the ongoing influenza pandemic, leveraging our regulatory and commercial capabilities across 17 markets in the region.'